We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
November 21, 2023
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the Piper Sandler 35th Annual Healthcare Conference on November 30.
November 10, 2023
Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-executive employees
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)